Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LY518674 (LY-674) decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis. LY518674 is an effective and selective PPARα agonist (EC50: 42 nM for human PPARα).
説明 | LY518674 (LY-674) decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis. LY518674 is an effective and selective PPARα agonist (EC50: 42 nM for human PPARα). |
ターゲット&IC50 | PPARα:42 nM (EC50 human) |
In vivo | LY518674 decreases triglycerides and increased HDL-C in vivo[2]. LY518674 significantly enhances apolipoprotein A-I (apoA-I) turnover without a major impact on steady-state levels of apoA-I or high-density lipoprotein-cholesterol (HDL-C) [3]. |
別名 | LY-674 |
分子量 | 409.48 |
分子式 | C23H27N3O4 |
CAS No. | 425671-29-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (610.53 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LY518674 425671-29-0 DNA Damage/DNA Repair Metabolism PPAR Peroxisome proliferator-activated receptors inhibit LY-674 Inhibitor LY-518674 LY 674 PPARα atherosclerosis LY674 LY 518674 inhibitor